Literature DB >> 2979754

A chemical comparison of methanesulfonyl fluoride with organofluorophosphorus ester anticholinesterase compounds.

A W Snow1, W R Barger.   

Abstract

The chemical reactivity and physical properties of methanesulfonyl fluoride (MSF) were quantitatively measured for direct comparison with those of isopropyl methylphosphonofluoridate (GB, sarin) and diisopropyl phosphorofluoridate (DFP). The chemistry involved reaction rate constant measurements of MSF hydrolysis and for reactions with phenolic, amine, oxime, hydroxamic acid, phenyl N-hydroxycarbamate, and hydroxylamine compounds and cupric imidazole and bipyridyl complexes. Analogous chemistry with GB and DFP occurred only for the nucleophilic reactions. MSF was substantially less reactive toward interactions involving hydrogen bonding, cupric complex coordination, and quaternary amine formation. Physical characterization included water solubility, vapor pressure, heat of vaporization, solubility parameter, hydrogen bond basicity, UV, IR, and NMR measurements. MSF is a much weaker hydrogen bond acceptor than the phosphorus esters. The hydrogen bond basicity beta-scale measurement provides a key insight to the chemical reactivity divergence of MSF and DFP or GB. Its unexpectedly low value is interpreted that MSF does not possess a site with sufficient basicity to be protonated by strong acid, to enter into hydrogen bonding, or for coordination with the cupric ion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979754     DOI: 10.1021/tx00006a009

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  3 in total

1.  Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.

Authors:  Donald E Moss; Ruth G Perez; Haruo Kobayashi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease.

Authors:  Donald E Moss; Ruggero G Fariello; Jörg Sahlmann; Isabel Sumaya; Federica Pericle; Enrico Braglia
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 3.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.